Back to today’s briefing

Story perspectives

Histotripsy Gains FDA Approval for Liver Tumors, UK Follows

10/9/2025

41 3 Full Breakdown

Summary

Story summary

Histotripsy received FDA approval for liver tumors in October 2023, with 95% technical success in a small study, though long-term recurrence concerns persist.
The UK approved Histotripsy for NHS use.
Histotripsy uses ultrasound to create microbubbles that destroy tumor tissue, enabling same-day discharge.
Rhode Island Hospital leads a randomized trial of immunotherapy with focused ultrasound for brain-metastasized lung cancer.

1 of 1

Story summary

Histotripsy received FDA approval for liver tumors in October 2023, with 95% technical success in a small study, though long-term recurrence concerns persist.
The UK approved Histotripsy for NHS use.
Histotripsy uses ultrasound to create microbubbles that destroy tumor tissue, enabling same-day discharge.
Rhode Island Hospital leads a randomized trial of immunotherapy with focused ultrasound for brain-metastasized lung cancer.